🇪🇺 Kyprolis in European Union

Kyprolis (carfilzomib) regulatory status in European Union.

Marketing authorisation

EMA

  • Application: EMEA/H/C/003790
  • Local brand name: Kyprolis
  • Status: approved

Kyprolis in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Oncology approved in European Union

Frequently asked questions

Is Kyprolis approved in European Union?

Yes. EMA has authorised it.

Who is the marketing authorisation holder for Kyprolis in European Union?

Amgen is the originator. The local marketing authorisation holder may differ — check the official source linked above.